NEW YORK, June 30, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Puma Biotechnology, Inc. (NYSE: PBYI), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4240-100free.
--
Keryx Biopharmaceuticals Inc. Analyst Notes
On June 18, 2014, Keryx Biopharmaceuticals, Inc. (Keryx) announced the issuance of U.S. Patents No. 8,754,257 and No. 8,754,258 by the U.S. Patent and Trademark Office. According to the Company, the patents, which will expire in 2024, claim pharmaceutical compositions comprising a form of ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm2/min, and orally administrable forms of ferric citrate prepared from a form of ferric citrate having an intrinsic dissolution rate of at least 1.88/mg/cm2/min, respectively. Ron Bentsur, CEO of Keryx, commented, "The patents that issued today are significant in that they link the Zerenex API with orally administrable dosage forms. Moreover, the timing of issuance, which is merely 6 months after the issuance of U.S. Patent No. 8,609,896 last December, provides substantiating evidence of our rapidly growing patent portfolio which covers many aspects of Zerenex and its API." The full analyst notes on Keryx are available to download freeof charge at:
http://www.analystsreview.com/Jun-30-2014/KERX/report.pdf
--
Puma Biotechnology, Inc. Analyst Notes
On June 25, 2014, Puma Biotechnology Inc. (Puma) stock increased 3.88% to end the day at $62.16 compared to the previous day's closing price of $59.84. The Company's stock grew 3.79% over the past five trading days compared to the Dow Jones Industrial Average which declined 0.23% and to S&P 500 which rose 0.13% during the same trading period. The full analyst notes on Puma are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/PBYI/report.pdf
--
Ligand Pharmaceuticals Incorporated Analyst Notes
On June 16, 2014, Ligand Pharmaceuticals Inc. (Ligand) announced positive data from a Phase 1 clinical trial with LGD-6972, Ligand's novel glucagon receptor antagonist, at the American Diabetes Association's 74th Scientific Sessions meeting underway in San Francisco. Presenting the first-in-human data, the Company reported that the trial demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus. The Company also reported that the trial demonstrates a positive response on fasting plasma glucose after a single dose. "Management of type 2 diabetes is one of the largest and fastest-growing global medical markets, and despite many approved therapies there is enormous need for new mechanisms to treat the disease. We believe that glucagon receptor antagonism is one of the most promising areas of novel research," commented Matthew W. Foehr, EVP and COO of Ligand. "We are highly encouraged by the results of this Phase 1 trial, which give us confidence in the continued development of this promising novel therapeutic with once-daily dosing and best-in-class properties. We consider the LGD-6972 program to be one of the most exciting in our portfolio of unpartnered assets." The full analyst notes on Ligand are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/LGND/report.pdf
--
Sagent Pharmaceuticals, Inc. Analyst Notes
On June 9, 2014, Sagent Pharmaceuticals, Inc. (Sagent) announced that it has been placed on the seventh spot on the Crain's 2014 Fast Fifty list, published by Crain's Chicago Business. This represents the Company's second consecutive year that it has been selected as one of the leading growth companies in Chicago. "We are honored to be ranked among an elite group of our peers in the Chicago area. This recognition is a true testament to the proven success of our business which has enabled rapid and consistent revenue growth and has distinguished the company as a leader in Chicago," said Jeffrey Yordon, Chairman and CEO of Sagent. "Our focus remains on identifying new ways to increase the breadth of our product portfolio and opportunities to innovate within the generic pharmaceutical industry. We attribute a great deal of our success to the collaborative efforts of our partners around the world, as well as to our employees' ongoing focus and commitment to the patients we serve." The Crain's Fast Fifty is an annual ranking that recognizes the fastest-growing companies in Chicago. The full analyst notes on Sagent are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/SGNT/report.pdf
--
Enanta Pharmaceuticals, Inc. Analyst Notes
On June 13, 2014, Enanta Pharmaceuticals, Inc. (Enanta) announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the Company's New Drug Application (NDA) of an investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The antiviral investigational regimen consists of ABT-450, which is Enanta's lead protease inhibitor developed through its collaboration with AbbVie. According to the Company, the NDA was submitted on April 21, 2014 supported by adequate data from a large clinical program being conducted by AbbVie, including six phase 3 studies of more than 2,300 GT1 patients in over 25 countries. The full analyst notes on Enanta are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/ENTA/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
